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Abstract: The potent HIV-1 inhibitor TRIM5 blocks HIV-1 infection by accelerating the 
uncoating of HIV-1. TRIM5 is known to form higher-order self-association complexes 
that contribute to the avidity of TRIM5 for the HIV-1 capsid, and are essential to inhibit 
infection;  these  higher-order  self-association  complexes  are  dependent  upon  an  intact  
B-box 2 domain. Even though the ability to form higher-order self-association complexes 
resembles the clathrin triskelion that forms a protein array, or cage, around the endocytic 
vesicle,  evidence  for  the  ability  of  TRIM5  to  assemble  a  similar  type  of  structure 
surrounding  the  HIV-1  core  has  been  lacking.  Recent  work  by  Ganser-Pornillos, 
Chandrasekaran and colleagues has now demonstrated the ability of the restriction factor 
TRIM5 to “cage” or “net” the HIV-1 core by forming an hexagonal array on the surface of 
the viral capsid [1]. This hexagonal array is strikingly similar in design to the array formed 
by  the  clathrin  triskelion  on  the  surface  of  the  clathrin-coated  endocytic  vesicle.  This 
remarkable finding represents an important advance on our understanding of the restriction 
factor  TRIM5, and suggests that TRIM5 cages the HIV-1 core in order to terminate 
infection. The present note discusses the implications of this discovery. 
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“Caging  the  beast”,  i.e., putting  the  HIV-1  core  in  a  cage,  seems  to  be  the  solution  to  all  our 
problems. Even though the battle with HIV-1 is far from over, Ganser-Pornillos and colleagues, in what 
could be considered a remarkable achievement in the HIV-1 field, demonstrated that the potent HIV-1 
inhibitor TRIM5 cages the HIV-1 core in order to terminate infection [1].  
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The rhesus macaque endogenously expressed protein tripartite motif 5 (TRIM5rh) potently blocks 
HIV-1 infection [2]; the restriction of HIV-1 by TRIM5rh is 100–1000 fold [3,4]. Because TRIM5 is 
a natural mechanism to block retroviruses such as HIV-1, researchers have tried to unlock the mystery 
behind the protein for many years now. Deciphering this mechanism could be a “Rosetta stone” for 
creating alternative treatments against HIV-1/AIDS.  
TRIM5rh  comprises  four  domains,  including  the  RING,  B-box  2,  coiled-coil  and  B30.2/SPRY 
(Figure 1A). The RING domain exhibits E3 ubiquitin ligase activity [5–9], and the contribution of this 
activity to the ability of TRIM5 to restrict HIV-1 is under intense investigation. The B-box 2 domain 
contributes to the avidity of TRIM5rh for the HIV-1 capsid [10–12]; the avidity of TRIM5rh for capsid 
is improved by TRIM5 inter-dimer interactions (Figure 1A). The coiled-coil allows TRIM5dimer 
formation  [8,9].  Lastly,  the  B30.2/SPRY  domain  of  TRIM5  provides  the  specificity  for  capsid 
recognition [13,14]. All four of these domains are important for HIV-1 restriction.  
Since  the  discovery  of  TRIM5  by  Matthew  Stremlau  [2],  the  field  recognized  the 
aggregation/assembly properties of the protein. Early studies demonstrated that mutations in the B-box 
2 domain of TRIM5, such as R121E, were apparently less prone to cause aggregation in the cytoplasm 
[10]; however, TRIM5α bearing this particular mutation did not restrict HIV-1 [10]. In quantitative 
capsid-binding assays, B-box 2 domain mutants, such as R121E, had a range of binding affinities to the 
HIV-1 capsid that were directly correlated with HIV-1 restriction [12]. Interestingly, TRIM5 B-box 2 
domain mutants are less prone to aggregate. Perhaps counter-intuitively, the field began to consider 
aggregation as an important factor for the ability of TRIM5 to restrict HIV-1 infection. This idea led 
to experiments that tested the ability of TRIM5 to self-associate into higher-order structures, as had 
been  shown  for  the  protein  clathrin  [15–17].  According to this simple model, one TRIM5 dimer 
associates  with  another  (Figure  1A)  [11,12],  and  these  higher-order  structures  directly  impact  the 
binding  affinity  of  TRIM5rh  for  the  HIV-1  capsid.  The  fact  that  TRIM5rh  was  able  to  undergo  
higher-order self-association suggested that TRIM5rh could potentially form a lattice or an array on top 
of the capsid, just like the clathrin triskelion in clathrin coated vesicles; however, there was not at that 
point  any  direct  evidence  to  support  this  hypothesis  for  TRIM5. Ganser-Pornillos and colleagues 
undertook  studies  to  physically  visualize  the  binding  of  TRIM5  to  the  HIV-1  capsid;  they 
demonstrated that TRIM5 proteins form an hexagonal array on top of the pre-assembled arrays of the 
HIV-1  capsid  protein.  Although  the  TRIM5  hexameric  array  had  a  striking  resemblance  to  the 
clathrin-coated vesicle seen by electron microscopy, it is important to mention that the final outcome of 
both processes is different. This remarkable observation provided new insights on the mechanism used 
by TRIM5rh to block HIV-1. 
By  using  negative-staining  electron  microscopy  of  the  TRIM5-21R  protein,  a  TRIM5rh  protein 
containing the RING domain of human TRIM21 [6], the authors visualized for the first time the ability 
of TRIM5-21R to spontaneously form two-dimensional paracrystalline hexagonal arrays [1]. Although 
these hexagonal arrays are formed at relatively low concentrations of protein (~10 M), the SPRY 
domain of TRIM5rh was not required for array assembly. Thus the RING, Bbox-2 and coiled-coil 
domains mediate the assembly of hexagonal arrays, where as the SPRY domain might be dictating 
where  these  hexagonal  arrays  form.  The  authors  went  on  to  confirm  that  mutants  of  the  B-box-2 
domain,  such  as  R121E,  have  reduced  binding  to  capsid,  as  a  result  of  impaired  higher-order  Viruses 2011, 3                                       
 
 
425 
self-association, in agreement with previous biochemical observations [12]. Furthermore, TRIM5-21R 
bearing the B-box 2 domain mutation R121E failed to form hexagonal arrays, implying that the B-box 
2  domain  might  be  involved  in  key  interactions  during  lattice  assembly.  The  fact  that  purified  
TRIM5-21R spontaneously assembles into hexameric arrays in the absence of capsid suggests that this 
process  might  be  regulated in the cellular environment by post-translational modifications or other 
factors [8,9]. As expected, the formation of hexagonal TRIM5rh arrays was facilitated when planar 
sheets of the capsid-nucleocapsid protein were added to the mixture.  
Taken together, these results have several important implications for viral restriction: 
(1)  According  to  the  model  proposed  by  Ganser-Pornillos  and  colleagues,  the  RING  domain  is 
localized on the surface of the core when the hexagonal arrays are formed. One possible scenario is that 
several RING domains could be recruiting E2 enzymes to the surface of the core to perform TRIM5rh 
ubiquitylation that will lead to core disassembly (Figure 1B). One could envision a model in which the 
self-ubiquitylation of TRIM5 is required to remove TRIM5 when forming hexagonal structures on 
the surface of the capsid [18–20]; removal of TRIM5 from the surface of the capsid will allow a 
decrease on the amount of particulate capsid during infection, thereby promoting rapid uncoating. In 
addition, our own unpublished results have suggested that the RING domain could also be playing a 
role in higher-order self-association, as shown for the B-box 2 domain. Indeed, RING domains have 
been shown to form higher-order interactions in other E3 enzymes [21–23]. 
(2)  The  B-box  2  domain  is  likely  to  be  the  anchor  in  the  array,  since  Ganser-Pornillos  and 
colleagues demonstrate that the B-box-2 domain mutation R121E does not form hexagonal arrays. This 
observation  agrees  with  previous  results  demonstrating  that  the  B-box  2  domain  is  important  for 
higher-order  self-association  (Figure  1A),  which  increases  the  avidity  of  TRIM5rh  for  the  HIV-1 
capsid [12].  
(3) The coiled-coil allows formation of the TRIM5rh dimer (Figure 1A) that is likely to be the 
minimal unit required for assembly of the hexagonal array, in analogy to the triskelion building block 
of the clathrin lattice [15–17].  
(4) The SPRY domain is likely to be in direct contact with capsid, as suggested by biochemical 
analyses from several laboratories. Thus the SPRY domain can provide specificity that dictates where 
this array will nucleate. The fact that the SPRY domain is not required for lattice formation opens the 
possibility that proteins related to TRIM5rh such as TRIM6, TRIM21 and TRIM34 are recruited to the 
array.  Recruitment  of  other  TRIM  proteins  to  the  array  might  be  important  for  the  fate  of  the  
HIV-1 core following array formation; therefore, it might be important to evaluate the fate of the capsid 
in cells containing endogenously expressed TRIM5rh where expression of the different TRIM5-related 
proteins such as TRIM6, TRIM34 and TRIM21 are knocked down. We have observed acceleration of 
uncoating only in cells over expressing TRIM5rh raising the possibility that this could be different in a 
scenario where different TRIMs are recruited to the core. This type of mixed array will make difficult 
the study of the contribution of TRIM5domains that contain enzymatic activity to restriction, such as 
the  RING  domain,  because  of  function  complementation  by  the  same  domains  from  other  TRIM 
proteins in the array.  
It is well-established biochemically that the presence of TRIM5rh during HIV-1 infection correlates 
with a decrease of particulate capsid, or what has been called “rapid uncoating/disassembly of the HIV-Viruses 2011, 3                                       
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1 core” [24–26]. However, when comparing HIV-1 core disassembly to the disassembly of the clathrin 
coat [15–17], the first thing that comes to mind is the source of energy for this event. Whether the 
energy  required  for  uncoating  post-TRIM5rh  binding  is  derived  from  the  removal  of  
self-ubiquitylated TRIM5rh proteins from the surface of the core or an independent source, it is likely 
that this process requires energy. Future experiments will determine the preceding steps to “caging” of 
the core to fully understand the restriction mechanism used by TRIM5rh.  
Figure 1. Current model for acceleration of uncoating mediated by TRIM5. (A) The linear 
box diagram represents the different domains of the TRIM5 protein with their respective 
known functions. TRIM5 forms a dimer, which is stabilized by the coiled-coil domain. In 
addition,  TRIM5  forms  higher-order  self-association  complexes  (TRIM5  inter-dimer 
association) that are dependent upon an intact B-box 2 domain. (B) According to the model 
proposed by Ganser-Pornillos and colleagues, TRIM5 initially cages the core. Because the 
RING domain is exposed on the surface of the core, we can envision the recruitment of E2 
enzymes that will ubiquitylate TRIM5. Removal of ubiquitylated TRIM5, for subsequent 
degradation, from the surface of the core will damage the core triggering the occurrence of 
premature uncoating. 
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